Trial ID or NCT#
This clinical trial studies gallium-68 (68Ga)-prostate specific membrane antigen (PSMA) (gallium Ga 68-labeled PSMA ligand Glu-urea-Lys[Ahx]) positron emission tomography (PET)/computed tomography (CT) or PET/magnetic resonance imaging (MRI) in identifying tumors in patients with prostate cancer that has come back after a period of improvement (recurrent). 68Ga-PSMA is a radioactive drug that may attach to specific prostate cancer cells and light up. Scanners, such as PET/CT or PET/MRI, can then be used to take pictures of the body to see where the cancer is. Using 68Ga-PSMA for PET/CT or PET/MRI may allow doctors to identify smaller tumors than standard methods.
68Ga-PSMA PET/CT or PET/MRI in the Evaluation of Patients With Prostate Cancer: A Feasibility Study
Contact us to find out if this trial is right for you.